Evaluating potential impacts of a preferential vaccine recommendation for adults 65 years of age and older on US influenza burden
Background: High-dose, adjuvanted, and recombinant influenza vaccines may offer
improved effectiveness among older adults compared with standard-dose, unadjuvanted …
improved effectiveness among older adults compared with standard-dose, unadjuvanted …
Evaluating equity-promoting interventions to prevent race-based inequities in influenza outcomes
Importance Seasonal influenza hospitalizations pose a considerable burden in the United
States, with BIPOC (Black, Indigenous, and other People of Color) communities being …
States, with BIPOC (Black, Indigenous, and other People of Color) communities being …
Relative Effectiveness and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Versus Egg-Based Inactivated Influenza Vaccine Among Adults Aged 18 …
Background Immunogenicity studies suggest that recombinant influenza vaccine (RIV) may
provide better protection against influenza than standard-dose inactivated influenza …
provide better protection against influenza than standard-dose inactivated influenza …
Geographic Variation in Racial Disparities in Receipt of High-Dose Influenza Vaccine Among US Older Adults
Background Racial disparities in receipt of high-dose influenza vaccine (HDV) have been
documented nationally, but whether small-area geographic variation in such disparities …
documented nationally, but whether small-area geographic variation in such disparities …
Regional Disparities in the Uptake of Differentiated Influenza Vaccines in the United States
Significant racial/ethnic inequities in the uptake of differentiated influenza vaccines (DIVs)
have been previously reported, though less is known about regional disparities. We …
have been previously reported, though less is known about regional disparities. We …
[PDF][PDF] Epidemiology Publish Ahead of Print
A Douros, D Abrahami, H Yin, OHY Yu, C Renoux - endo-smc.umin.jp
Background: Case reports have suggested a link between dipeptidyl peptidase-4 (DPP-4)
inhibitors, antidiabetic drugs used as second-to third-line treatments, and incidence of …
inhibitors, antidiabetic drugs used as second-to third-line treatments, and incidence of …